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Abstract
Background: Elevated pregnancy estrogen levels are associated with increased risk of developing
breast cancer in mothers. We studied whether pregnancy weight gain that has been linked to high
circulating estrogen levels, affects a mother's breast cancer risk.
Methods: Our cohort consisted of women who were pregnant between 1954–1963 in Helsinki,
Finland, 2,089 of which were eligible for the study. Pregnancy data were collected from patient
records of maternity centers. 123 subsequent breast cancer cases were identified through a record
linkage to the Finnish Cancer Registry, and the mean age at diagnosis was 56 years (range 35 – 74).
A sample of 979 women (123 cases, 856 controls) from the cohort was linked to the Hospital
Inpatient Registry to obtain information on the women's stay in hospitals.
Results: Mothers in the upper tertile of pregnancy weight gain (>15 kg) had a 1.62-fold (95% CI
1.03–2.53) higher breast cancer risk than mothers who gained the recommended amount (the
middle tertile, mean: 12.9 kg, range 11–15 kg), after adjusting for mother's age at menarche, age at
first birth, age at index pregnancy, parity at the index birth, and body mass index (BMI) before the
index pregnancy. In a separate nested case-control study (n = 65 cases and 431 controls),
adjustment for BMI at the time of breast cancer diagnosis did not modify the findings.
Conclusions: Our study suggests that high pregnancy weight gain increases later breast cancer
risk, independently from body weight at the time of diagnosis.
Background
Sensitivity of the breast to hormones and environmental
exposures varies throughout a woman's life span [1]. Dur-
ing pregnancy, the breast undergoes extensive changes in
preparation for lactation. High estrogenicity during preg-
nancy causes marked cellular proliferation, in both in the
normal and tumor cells. Normal breast cells differentiate
to milk-secreting alveoli, while tumor cells, if present,
continue to multiple and eventually form a detectable
tumor. These two events probably explain the dual effect
of pregnancy on breast cancer risk: pregnancy before age
20 reduces, whereas first pregnancy after age 30 increases,
breast cancer risk [2]. In young women, pregnancy may
eliminate future targets for neoplastic changes by differen-
tiating target cells [3]; the breast tissue of older first time
mothers is more likely to have acquired malignant cells
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environment.
Women whose pregnancy estrogen levels are elevated are
at an increased risk of breast cancer. For example, women
who took the synthetic estrogen diethylstilbestrol (DES)
during pregnancy are at an increased risk of developing
breast cancer [4], as are women who suffered from severe
pregnancy nausea [5] or who gave birth to heavy new-
borns [6]. Both nausea in pregnancy and high birth
weight are linked to elevated pregnancy estrogen levels
[7,8] Conversely, pregnant women having high alpha
feto-albumin levels [9,10], or suffering from hypertension
or pre-eclampsia [11,12], exhibit a reduced risk. Alpha
feto-protein has direct antiestrogenic activity and binds
estrogens, reducing their biological availability [13,14].
Hypertension during pregnancy is linked to reduced estro-
gen and increased testosterone levels [15]. A recent study
in which estrogen levels were measured in stored blood
samples of pregnant women later diagnosed with breast
cancer, provides direct evidence in support of high estro-
gen and low progesterone levels in increasing maternal
breast cancer risk [16]. However, some studies have failed
to find an association between pregnancy estrogen levels,
determined indirectly, and maternal breast cancer risk
[11,17].
Adipose tissue aromatizes androgens to estrogens, and
thus high body mass index (BMI) is linked to elevated
estrogen levels in postmenopausal women [18]. Some
studies suggest that high pregnancy weight gain may be
associated with increased pregnancy estrogen levels [19],
although this has not been confirmed in more recent stud-
ies [20,21]. The goal of this study was to determine




The study population was a historic cohort of women
pregnant between 1954 and 1963 in Helsinki, Finland (n
= 4,090). The cohort was a sample gathered for a study on
hormone exposure, including 2,022 exposed, 2,062 con-
trols and 6 women with unknown hormone exposure sta-
tus. Information on the cohort was collected from the
maternity cards of municipal maternity centers, which are
used by most pregnant Finnish women. The hormone-
exposed women had been prescribed estrogen or proges-
tin drugs during pregnancy to prevent early abortion or
preterm delivery. For each exposed woman, a woman next
in the maternity center file who gave birth during the
same year and had not been prescribed hormones during
pregnancy, was chosen as a control. The cohort has been
previously prescribed in detail [22,23]. There were no dif-
ferences in breast or other estrogen-dependent cancers
between hormone-exposed and control mothers [22]. Vis-
its to a private doctor were used as an indicator of socio-
economic status, since no information on education or
occupation at the time of the index pregnancy was
available.
Cancer cases were identified through a record linkage to
the national cancer registry until June 2001. Mortality and
emigration data were obtained from the population regis-
try until August 2001. The linkage between the cohort and
the registries was based on a unique personal identifica-
tion number.
Inclusions and exclusions
Inclusion criteria were the following: first and last visit at
the maternity center between 4–45th gestation weeks, the
time between the body weight measurements 3–300 days,
and delivery between 22–45th gestation weeks. For each
mother, the gestation week she gave birth was determined
by using the date of estimated timing of delivery. Women
who did not fulfill these criteria were excluded (Fig. 1). In
addition, women with multiple births were excluded
because their weight gain is not comparable to that of
mothers of singletons. Mothers with pre-eclampsia or
eclampsia were excluded because they accumulate weight
as fluid retention during pregnancy, and have been
reported to have a reduced breast cancer risk [11,12].
Pregnancy weight gain was first calculated as the differ-
ence between the first and last visit to maternity center.
However, this window varied considerably among
included mothers (range 3–295 days). The time-period of
calculated weight gain was therefore adjusted by extrapo-
lating a line for each mother to reflect her weight increase
during pregnancy. The calculations are described in detail
in Additional File 1. After the unstable period of early
pregnancy, a mother's weight increases linearly [24].
Mothers usually begin to gain weight after the first trimes-
ter (e.g [25]). We extrapolated the line separately for 0–
15th (Line A) and 15–40th gestation weeks (Line B) for
each mother. Weight gain was extrapolated to continue
until 40th gestation week for all mothers, although 22.2%
of mothers delivered at 39th gestation week or before.
For mothers for whom both Line A (n = 2,143) and Line
B (n = 2,184) were available, total pregnancy weight gain
was calculated by adding the extrapolated weight gains
from both periods. Thus, total pregnancy weight gain
could be extrapolated only for 2,089 women. Cases and
controls (66.5% vs 65.0%) did not differ concerning the
number of available weight measurements. For the rest of
the women, either the first weight measurement was later
than 24th gestation week, the last weight measurement
was before 30th gestation week, or information on pre-Page 2 of 10
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Study population and exclusions.
Study population (n=4,090, of which 232 breast cancer cases). 
      Excluded  
Unknown hormone drug exposition status (n=6), 
(no breast cancer cases).    
      Excluded 
Twins (n=57) and triplets (n=2), (4 breast cancer cases) 
      Excluded 
Miscarriages (n=273) and abortions (n=19), (18 breast cancer cases) 
      Excluded 
Mothers with (mild) pre-eclampsia (n=280), (12 breast cancer cases) 
      Excluded 
Incorrect dates concerning first or last visits at the maternity 
centers or delivery (n=244), (13 breast cancer cases). 
      Excluded 
Data on total pregnancy weight gain not available (n=1,120), 
(62 breast cancer cases) 
Final study population: n=2,089, 123 breast cancer cases.  
Case-control study:  
A sample of 123 cases and 856 controls was linked to the Hospital Inpatient Register. 
Information on body weight at the hospital visit (mean 29 years after pregnancy) was available 
for 65 cases and 431 controls (6.6 controls/case). Page 3 of 10
(page number not for citation purposes)
BMC Women's Health 2004, 4:7 http://www.biomedcentral.com/1472-6874/4/7pregnancy weight, weight at the first or the last visit, or
timing of the visits was not available. As indicated above,
these subjects were excluded from the analyses.
We compared the characteristics of the mothers who were
excluded (n = 2,001) to the characteristics of the mothers
in the final study population for whom total pregnancy
weight gain could be determined (n = 2,089). The two
groups were similar in regard to breast cancer incidence,
age at menarche, height and the frequency of visits to a
private doctor. However, the excluded mothers were older
(mean: 27.1 years vs. 26.5 years, p < 0.001), heavier (58.7
kg vs. 57.3 kg, p < 0.001; body mass index, BMI: 22.3 kg/
m2 vs. 21.8 kg/m2, p < 0.001), older at first birth (25.2
years vs. 24.7 years, p = 0.016), had more children during
index pregnancy (1.92 vs. 1.81 at index birth, p < 0.001),
and were more often exposed to estrogen or progestin
drugs (50.3% vs. 48.6%, p = 0.021). Their children were
shorter (mean 49.3 cm vs. 50.3 cm, p < 0.001) and
weighed less (mean 3,310 g vs. 3,472 g, p < 0.001), sug-
gesting that excluded mothers' pregnancy weight gain
might have been lower. It is probable that exclusion of
these women had no major effect on the findings.
The case-control study
A nested case-control study was performed to determine
whether later weight development confounded the associ-
ation between pregnancy weight gain and breast cancer
risk. A sample of women was chosen from the final cohort
(n = 2,089) that included all breast cancer cases with data
on pregnancy weight gain (n = 123). For each case, we
chose seven randomly selected controls (n = 856) who
were born in the same year as the case. These 979 women
were linked to the Hospital Inpatient Registry to obtain
information on the women's stays in hospitals. 117 cases
were identified with a hospital visit in average 0.4 months
after breast cancer diagnosis (median 0.0, range from -
16.3 to 17.2), and of these cases information on body
weight and height was available for 65 (53% of 123
cases). Among the controls, 699 had been a patient in a
hospital at a similar age than their respective cases (maxi-
mum difference +/-5 years), and 431 of them had weight
and height available in the hospital archives (50% of 856
controls, 6.6 controls/case).
The breast cancer cases with no information on later body
weight did not differ from the cases used for the nested
case-control analysis. The controls with no information
on later body weight were approximately 1.5 years older
at the time of the hospital visit than the controls included
to the study (p = 0.027).
Statistical analysis
Statistical significance of possible differences in baseline
characteristics of the study population, pregnancy weight
gain and postpartum weight loss and weight retention by
tertiles of pregnancy weight gain was tested by using anal-
ysis of variance for continuous variables and χ2-test for
proportions. The incidence of breast cancer per 100,000
person years was counted by groups of 5 kg pregnancy
weight gain, tertiles of pregnancy weight gain and tertiles
of postpartum weight retention. Person years were calcu-
lated from the delivery to the diagnosis of breast cancer or
other endpoint including death, emigration or end of the
study.
The association between pregnancy weight gain and
breast cancer risk was further examined using a Cox
regression model. Total pregnancy weight gain was
included as a categorical covariate (tertiles) in the model.
Age at menarche, age at first birth, age at index pregnancy,
BMI before pregnancy, and parity (at index birth) were all
used as continuous covariates in the model. Postpartum
weight retention 51 days after delivery (mean) was later
added to the model.
The incidence of breast cancer was counted and the Cox
regression model was carried out also separately for pre-
and postmenopausal breast cancers. Information on the
age at menopause was not available. Therefore all women
were expected to have menopause at the age of 50 years.
In the case-control study, weight and BMI change between
pre-pregnancy and at the time of later hospital visit were
compared between the tertiles of pregnancy weight gain
(analysis of variance). A Cox regression model that
included later BMI was also used to analyze the data.
Results
In the cohort, 123 (5.9%) women developed breast cancer
during the mean follow-up of 38.9 years. The mean age at
diagnosis was 56.0 years (range 35–74). Background char-
acteristics and index pregnancies are described by tertiles
of pregnancy weight gain in Table 1. Low pregnancy
weight gain (<11 kg) was associated to slightly higher ages
during index pregnancy, during first pregnancy and at
menarche, and to lower height, higher BMI before preg-
nancy, higher gestation weeks at delivery, lower weight of
the placenta, smaller infant and lower proportion of users
of estrogen drugs compared to women with higher preg-
nancy weight gain (11–15 kg or >15 kg).
Weight development during and after pregnancy is pre-
sented by tertiles of pregnancy weight gain in Table 2.
Higher weight gain during pregnancy was associated to
higher weight loss after delivery, but also to higher weight
retention and BMI at the postpartum check-up visit.Page 4 of 10
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The mean BMI before pregnancy was 21.8 kg/m2 and the
mean total extrapolated weight gain during pregnancy
was 13.3 kg (range -5.0–33.1 kg) in our cohort. Average
pregnancy weight gain (and range) was 13.1 kg (-3.0–
33.1) among primiparas, 13.5 kg (1.9–30.7) among
women who gave birth to their second child and 13.2 kg
(-5.0–32.4) among women who gave birth to at least their
third child. The incidence of breast cancer by 5 kg catego-
ries of total pregnancy weight gain is shown in Table .
Higher pregnancy weight gain was associated with a
higher incidence of breast cancer. However, the number
of women in some of the weight gain categories was
small, and therefore the statistical analyses were carried
Table 1: Background characteristics of index pregnancy, by tertiles of estimated pregnancy weight gain. Means (and SD) or percentiles 
are shown.
Pregnancy weight gain (kg)
< 11 (n = 696) 11–15 (n = 697) >15 (n = 696) p-value
Background
Mother's age (year)1 27.0 (5.3) 26.2 (4.9)2 26.2 (5.0)2 0.006
Mother's age at first birth (years) 25.2 (4.8) 24.4 (4.4)2 24.5 (4.4)2 0.003
Married (%)1 97 98 98 0.720
Visits to a private doctor (%)1 49 45 51 0.053
Mother's height (cm) 161.2 (5.5) 162.0 (5.2)2 162.9 (5.2)23 <0.001
Mother's body mass index before pregnancy (kg/m2) 22.3 (2.9) 21.6 (2.3)2 21.6 (2.5)2 <0.001
Mother's age at menarche (year) 14.2 (1.6) 13.9 (1.6)2 13.8 (1.6)2 <0.001
Regular menstrual cycles (%) 94 93 95 0.296
Parity (at index birth) 1.8 (1.1) 1.8 (1.0) 1.8 (1.1) 0.896
Index pregnancy
Gestation weeks at delivery (week) 40.6 (2.2) 40.4 (2.1) 40.2 (2.2)2 <0.001
Exposed to estrogens (%) 45 49 52 0.040
Weight of the placenta (g)4 603 (112) 634 (124)2 661(205)23 <0.001
Infant height (cm)4 50.0 (2.3) 50.3 (2.1) 50.6 (2.5)23 <0.001
Infant weight (g) 3,376 (514) 3,466 (504)2 3,577(544)23 <0.001
Low birth weight (%) 5 3 3 0.305
1 at the time of index pregnancy
2 a statistically significant difference compared to the lowest tertile (<11 kg)
3 a statistically significant difference compared to the middle tertile (11–15 kg)
4 total n = 2,055–2,089, except for placental weight (n = 1,217) and infant height (n = 2,006)
Table 2: Weight gain during and after pregnancy by tertiles of estimated pregnancy weight gain. Means (and 95% confidence intervals) 
are shown.
Pregnancy weight gain (kg)
<11 (n = 696) 11–15 (n = 697) >15 (n = 696) p-value
Mother's weight gain (kg)
Total weight gain, weeks 0–40 8.6 (8.5–8.8) 12.9 (12.9–13.0) 18.2 (18.0–18.4) <0.001
Weight after delivery1
Weight change from 40th week (kg) -7.4 (-7.7 – -7.2) -8.8 (-9.0 – -8.6) -10.6 (-10.9 – -10.3) <0.001
Weight compared to pre- pregnancy weight (kg) +1.3 (1.0–1.6) +4.1 (3.8–4.3) +7.6 (7.3–8.0) <0.001
BMI (kg/m2) 22.6 (22.4–22.9) 23.2 (22.9–23.4) 24.4 (21.1–24.6) <0.001
Weight at the hospital visit2 (n = 167) (n = 170) (n = 159)
Change from pre-pregnancy weight (kg) + 6.4 (5.1–7.8) +10.4 (9.0–11.9) +12.5 (10.8–14.3) <0.001
BMI (kg/m2) 25.0 (24.3–25.6) 25.6 (25.0–26.2) 26.3 (25.6–27.0) 0.021
Change from pre-pregnancy BMI (kg/m2) + 2.4 (1.9–3.0) + 4.0 (3.4–4.6) + 4.8 (4.1–5.4) <0.001
1 on postpartum day 51, range 40–78, total n = 1,314–1,713
2 29 years after pregnancy in average, range 9–47Page 5 of 10
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The incidence of breast cancer was significantly higher in
mothers in the highest tertile of pregnancy weight gain
(15–33 kg), when compared to the middle tertile (11–15
kg) (p = 0.04). Breast cancer incidence was lowest in the
middle tertile, but no differences in the risk were seen in
the mothers of the lowest tertile of weight gain (less than
11 kg), when compared with the other two categories.
All analyses were initially carried out separately for pre-
and postmenopausal breast cancers. The results for post-
menopausal women were similar to the results for the
whole cohort (results not shown). The incidence of pre-
menopausal breast cancer was too low for statistical
analysis and pre- and postmenopausal breast cancers were
not separated further in the analyses. When these analyses
were restricted to mothers who delivered after 39th gesta-
tion week, results were similar than in the whole cohort
(results not shown).
The incidence of breast cancer was calculated separately
for early (0–15th gestation weeks) and later pregnancy
weight gain (15–40th gestation weeks). Early pregnancy
weight gain was not associated with breast cancer risk. The
impact of later pregnancy weight gain was similar to the
impact of total weight gain, but more modest (results not
shown).
Multivariate analysis
Both unadjusted and multivariate adjusted rate ratios and
confidence intervals for the risk of breast cancer are pre-
sented in Table 4. In the Cox regression model, mothers
Table 3: Breast cancer incidence (per 100,000 person years, py) by estimated total weight gain (weeks 0–40).
Weight gain (kg) Breast cancer cases (n) Number of women Py 171 Incidence 0
<0 0 4
0–4.99 1 42 1,677 60
5–9.99 23 423 16,614 138
10–14.99 53 954 37,266 1421
15–19.99 33 508 19,498 169
≥20 13 158 6,086 213
total 123 2,089 81,312 151
1 Breast cancer incidence was exceptionally high (200 per 100,000) in mothers who gained 10–10.99 kg during pregnancy.
Table 4: Incidence (per 100,000 person years) and unadjusted and adjusted rate ratios (RR)1 and confidence intervals (CI) on the Cox 










Pregnancy weight gain (kg) 0.09
<11 39 696 143 1.18 (0.74–1.88) 1.11 (0.68–1.83)
11–15 33 697 121 1.00 (ref.) 1.00 (ref.)
> 15 51 696 190 1.59 (1.03–2.47) 1.62 (1.03–2.53)
Postpartum weight retention (kg)2 0.33
<3 26 558 121 1.00 (ref.) 1.00 (ref.)
3–5 35 539 170 1.29 (0.72–2.34) 1.36 (0.73–2.54)
>5 35 545 170 1.54 (0.87–2.74) 1.56 (0.85–2.86)
Pregnancy weight gain (kg), case-control study3
<11 19 167 - - 1.01 (0.54–1.91) 0.95 (0.49–1.84)
11–15 19 170 - - 1.00 (ref.) 1.00 (ref.)
> 15 27 159 - - 1.50 (0.83–2.69) 1.48 (0.81–2.69)
1 Adjusted for age at menarche, age at first birth, age at index pregnancy, parity (at index birth) and body mass index (BMI) before pregnancy. For 
the RR for postpartum weight retention, adjusted also for pregnancy weight gain (weeks 0–40).
2 Weight on postpartum day 51, range 40–78, compared to pre-pregnancy weight.
3 Adjusted for age at menarche, age at first birth, age at index pregnancy, parity (at index birth), BMI before pregnancy, and BMI during the hospital 
visit in average 29 years after pregnancy.Page 6 of 10
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had a 1.62-fold higher risk for breast cancer compared to
mothers in the middle tertile (average weight gain 12.9
kg), when age at menarche, age at first birth, age at index
pregnancy, BMI before pregnancy and parity at index birth
were included in the model. To assess the sensitivity of
these analyses, the lowest and highest weight gain groups
were used as reference groups. When the lowest weight
gain group was the reference group, no differences among
the groups were seen. However, when the highest weight
gain group was the reference group, women with average
weight gain had significantly lower risk of breast cancer
(multivariate adjusted RR 0.62, 95% CI 0.40–0.97).
When the middle tertile of weight gain was again used as
the reference group and the analysis was restricted to
mothers who delivered after 39th week of gestation, the
results were essentially similar although statistically not
significant (data not shown). The results did not either
change when adjusted additionally for the year of index
birth. The increased breast cancer risk in the highest tertile
of pregnancy weight gain was found only for postmeno-
pausal breast cancer (relative risk, RR = 1.80, 95% confi-
dence interval, CI 1.05–3.07, p = 0.03). The RR for
premenopausal cancer was 1.00 (95% CI 0.40– 2.48, p =
0.99). However, the number of premenopausal breast
cancer cases with the information on all variables in the
model was too low (n = 25) to yield sufficient power.
No statistically significant differences in breast cancer risk
were observed between the tertiles of postpartum weight
retention, determined approximately 51 days after deliv-
ery (Table 4).
Other results
Later age at menarche was marginally related to a
decreased risk of breast cancer (adjusted RR = 0.99, 95%
CI 0.97–1.00). Mother's age at the time of first pregnancy
or at the index pregnancy, parity at index birth or BMI
before pregnancy were not statistically significantly asso-
ciated with the risk of breast cancer. The results were sim-
ilar when height and weight were used as separate
variables in the model, instead of BMI.
Lower pre-pregnancy BMI was associated with higher
weight gain during pregnancy (p < 0.001) and higher
postpartum weight retention (p = 0.003), but not with
postpartum weight loss. The differences in the incidence
of breast cancer were not statistically significant between
the pre-pregnancy BMI-categories.
The case-control study
Women who gained at least 15 kg weight during preg-
nancy had a higher BMI at the time of later hospital visit
(29 years after pregnancy in average) than women who
gained <11 kg weight during pregnancy (p = 0.021) (Table
2.). Changes in body weight (p < 0.001) and BMI (p <
0.001) were also higher in women who gained 11–15 kg
or >15 kg compared to women who gained <11 kg during
pregnancy. These findings are in agreement with earlier
reports showing a link between excessive pregnancy
weight gain and becoming overweight/obese later on
[26,27].
The time window between pregnancy and assessment of
BMI during later hospital visit was similar among the ter-
tiles of pregnancy weight gain (29.2 vs. 30.0 vs. 30.1 years,
p = 0.397). In the Cox regression model, women's later
BMI at the time of diagnoses was not associated with
breast cancer risk (adjusted RR = 0.96, 95% CI 0.90–1.04).
Further, results relating to pregnancy weight gain and
breast cancer risk were not altered by adding data on later
BMI to the model (Table 4). It is to be noted that since
fewer women were included to this analysis, the effect of
pregnancy weight gain did not reach statistical
significance.
Discussion
The results obtained in our study indicate that higher than
recommended pregnancy weight gain increased mothers'
risk of developing breast cancer. Thus, women who
gained more than 15 kg during pregnancy had a 62%
increase in breast cancer risk, compared to those who
gained between 11–15 kg. The Institute of Medicine
(IOM) published their most recent recommendations for
pregnancy weight gain in 1990 [28]. The recommended
pregnancy weight gain in the USA is 11.5–16 kg for
women with normal pre-pregnancy BMI; i.e., they are not
obese or underweight. Pregnancy weight gain recommen-
dations are lower (7–11.5 kg) for overweight women and
higher (12.5–18 kg) for underweight women. As seen in
Table 3, the incidence of breast cancer in our study was
highest among women who gained more than 20 kg
during pregnancy, suggesting that the increase in risk may
apply primarily to women at the most extreme range of
pregnancy weight gain.
An increase in breast cancer risk was seen mostly in
women who were diagnosed with this disease after age 50
and thus were postmenopausal. However, the number of
premenopausal breast cancers was low in the cohort, and
we cannot exclude the possibility that pregnancy weight
gain may also increase the risk of premenopausal breast
cancer.
Data generated in epidemiological studies rarely provide
causal relationships. We propose four different mecha-
nisms that may link high pregnancy weight gain to a later
increase in breast cancer risk. First, weight retention in
women who gained excessive amounts of weight duringPage 7 of 10
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years. Women prone to postpartum weight retention
might also be prone to long-lasting weight gain after preg-
nancy [29], and high BMI during postmenopausal years
increases breast cancer risk [26]. To examine this possibil-
ity, information on body weight at the time of breast can-
cer diagnosis was obtained. If the association between
pregnancy weight gain and breast cancer risk was affected
by later weight development, breast cancer cases should
have had higher BMI at the time of diagnosis. As this was
not the case, we propose that high pregnancy weight gain
increases breast cancer risk independently from body
weight at the time of diagnosis.
Another alternative is that women who gained an exces-
sive amount of weight during pregnancy may have had
higher pregnancy hormone and growth factor levels than
women who gained within the recommended range, stim-
ulating the growth of existing malignant cells in the
breast, leading to development of a detectable tumor. Sev-
eral studies have shown that markers of high pregnancy
estrogen levels increase mother's breast cancer risk [4-6,9-
12,16]. Estrogen levels may correlate with high pregnancy
weight gain [19], but two recent studies have not con-
firmed this observation [20,21]. Other possible hormones
that could be mediating the effect of pregnancy weight
gain on breast cancer risk include leptin. Leptin levels cor-
relate strongly with BMI [27], also during pregnancy [30],
and leptin is suggested to increase breast cancer risk [31].
We did not have any biological samples available for hor-
mone measurements.
It is known that high hormone levels increase the prolifer-
ation of normal breast cells that then is accompanied by
increased genomic instability and accumulation of DNA
adducts [16,32]. Thus, the third explanation is that high
pregnancy weight gain increased the likelihood of DNA
damage and mutations in genes that initiate breast cancer.
Since the window between index pregnancy and diagnosis
of breast cancer was approximately 30 years, there was
enough time for the initiation to have taken place during
pregnancy.
Finally, known and unknown causes of breast cancer may
have confounded the results. For example, these causative
factors might be more common in women who gain
excessive amounts of weight during pregnancy or they
caused women to gain excessive amounts of weight dur-
ing pregnancy. A theoretical example is a gene mutation/
polymorphism that could both make a woman more
prone to gain weight during pregnancy and increases
breast cancer risk.
Methodological limitations have to be considered when
interpreting the results, and they include high rate of
exclusion and an exposure to estrogenic drugs during
pregnancy. Of the 4,090 women available for the study,
48.9 % were excluded for reasons listed in Figure 1 (109
of which were diagnosed with breast cancer). Total
pregnancy weight gain could be extrapolated only for
2,089 women, of which 123 had developed breast cancer.
Other information on background and index pregnancies
indicated that the excluded women might have gained
less weight during pregnancy than the final study popula-
tion (see chapter Inclusions and exclusions). However, we
found no evidence that breast cancer incidence was differ-
ent between the women excluded and included to the
study.
Some women in our cohort had been exposed to synthetic
estrogens during pregnancy to avoid a threatening miscar-
riage, and this exposure might have affected the results.
However, it was the initial reason for obtaining informa-
tion from pregnant women, and we found no effect of the
drug exposure on the incidence of breast cancer. We are
not aware of any other cohort that could be used to assess
the link between pregnancy weight gain and breast cancer
risk, but if such a cohort becomes available, and it is not
potentially compromised by high rate of exclusion of sub-
jects or an exposure to drugs during pregnancy, the
present results can be either confirmed or nullified. Fol-
low-up of "old" cohorts similar to ours is rarely possible,
making our study relatively unique.
Another area of potential source for errors is the variability
in time period between the weight measurements during
pregnancy (range 3–295 days), requiring us to extrapolate
the pregnancy weight gain for each woman. This step also
has been successfully used in other studies [33]. A further
weakness of the study was that no information on weight
gain in previous and subsequent pregnancies was availa-
ble. Therefore, we cannot exclude the possibility that a
woman who did not develop breast cancer and during the
index pregnancy gained less than 15 kg, might have had
subsequent pregnancies that were characterized by exces-
sive weight gain.
Finally, in the case-control study that determined the
impact of body weight at the time of diagnosis on breast
cancer risk, information on this weight was obtained only
for 53% of the cases and 50% of the controls. However,
the direction of bias rising from exclusion may have
diluted the effect, rather than caused it.
In conclusion, our findings suggest that excessive preg-
nancy weight gain increased later risk of developing breast
cancer. This association needs to be further confirmed in
prospective studies.Page 8 of 10
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